PAI-1
PAI-1, encoded by SERPINE1, is a primary member of the serpin super-family and functions as an essential inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen PAI-1 is up-regulated in various pathological states such as vascular diseases, obesity, metabolic syndrome and particularly various types of cancer. PAI-1 expression is quite different in diverse cancer cell lines. PAI-1 is also correlated with poor outcome in several other cancer subtypes, particularly in node-negative breast cancer, ovarian serous carcinoma. As an important regulator of the fibrinolytic system, PAI-1 plays a pivotal role in acute thrombotic events. PAI-1 facilitated invasion and lung metastasis via promoting MMP-13 expression and secretion in osteosarcoma cells, and PAI-1 as well as MMP-13 concomitant expression was significantly associated with lung metastasis of osteosarcoma through clinical samples analysis.
High PAI-1 expression might increase the risk of head and neck carcinoma metastasis via immunohistochemical analysis and further overexpression of PAI-1 accelerated head and neck cancer cell migration mediated by the activation of PI3K/AKT pathway. PAI-1 has also been found to promote cell proliferation in fibromatosis and pheochromocytoma. The roles of PAI-1 in cancer might vary with each experimental condition, especially the cancer type. Moreover, PAI-1 may also be involved in immunosuppression, a key condition for rapid tumor progression. Recently, it was reported that TGF-β could enhance PAI-1 secretion in NSCLC dependent on Smad3 phosphorylation, and PAI-1 in return could strengthen TGF-β signaling in tumor associated macrophages via the activation of NF-κB/IL-6/STAT3 pathway, forming an immunosuppressive feed-forward loop.
References
1.Li S,et al. Biomed Pharmacother. 2018;105:83–94.
High PAI-1 expression might increase the risk of head and neck carcinoma metastasis via immunohistochemical analysis and further overexpression of PAI-1 accelerated head and neck cancer cell migration mediated by the activation of PI3K/AKT pathway. PAI-1 has also been found to promote cell proliferation in fibromatosis and pheochromocytoma. The roles of PAI-1 in cancer might vary with each experimental condition, especially the cancer type. Moreover, PAI-1 may also be involved in immunosuppression, a key condition for rapid tumor progression. Recently, it was reported that TGF-β could enhance PAI-1 secretion in NSCLC dependent on Smad3 phosphorylation, and PAI-1 in return could strengthen TGF-β signaling in tumor associated macrophages via the activation of NF-κB/IL-6/STAT3 pathway, forming an immunosuppressive feed-forward loop.
References
1.Li S,et al. Biomed Pharmacother. 2018;105:83–94.
Metabolic Enzyme/Protease
11β-HSD(15)
15-PGDH(1)
ACC(8)
ACE(7)
AChE(17)
Adenylate Cyclase(10)
ALDH(14)
Aldose Reductase(5)
Aminopeptidase(15)
BACE(15)
Casein Kinase(33)
CAT(5)
Cathepsin(8)
CETP(10)
COMT(2)
CPG2(1)
CYPs(6)
Decarboxylase(3)
Dehydrogenase(43)
DGAT(4)
Dopamine beta-hydroxylase(2)
DPP(20)
Elastase(6)
FAAH(10)
Factor Xa(20)
Fatty Acid Synthase(7)
Ftase(2)
FXR(16)
Glucokinase(1)
GSNOR(2)
Guanylate Cyclase(5)
HMGCR(11)
IDH(6)
IDO(12)
IMPDH(2)
LDH(2)
LDL(2)
Lipase(8)
Lipid(5)
MAGL(2)
MAO(38)
MMP(30)
NAMPT(5)
Neprilysin(4)
Other Targets(4)
P450(46)
PAI-1(5)
Phosphatase(24)
Phospholipase(18)
PPAR(56)
Protein Phosphatase/PTP(6)
Renin(7)
Retinoid Receptor(15)
SCD(4)
Steroid Sulfatase (STS)(2)
Thioredoxin(1)
TPH(5)
Transferase(10)
Vitamin(37)
Xanthine Oxidase (XAO)(1)